Italy To Relax Biosimilar Switching Rules In Cost-Savings Effort
Executive Summary
The move towards greater acceptance of biosimilars is likely to be spurred by new guidance from the Italian regulatory agency AIFA giving more support to biosimilar switching, and by the declaration by a key European medical association that switching infliximab products in IBD patients is “acceptable.”
You may also be interested in...
Scrip Asks… Is The Biosimilar Cost-Saving Theory Sustainable?
Scrip asks industry whether the promise of biosimilars producing substantial cost-savings is a sustainable model to help healthcare systems afford the next wave of expensive biologics. Drug developers and trade associations comment on the caveats still in play when it comes to biosimilars, cost-cutting and market access.
Scrip Asks… Is The Biosimilar Cost-Saving Theory Sustainable?
Scrip asks industry whether the promise of biosimilars producing substantial cost-savings is a sustainable model to help healthcare systems afford the next wave of expensive biologics. Drug developers and trade associations comment on the caveats still in play when it comes to biosimilars, cost-cutting and market access.
Biosimilars Boost In Europe: 2017 Kicks Off With Three Approvals And Backing From ESMO
With three new approvals in January, the first anticancer about to be authorized, and a vote of confidence from the oncology physicians’ body ESMO, the European biosimilar medicines sector already seems to be picking up momentum in 2017.